Search research articles
Contact Us
Filters
Showing results (31-40 of 81) with videos related to
Page
of 9
Sort By:
Archives of Dermatological Research
|
March 12, 2025
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Archives of Dermatological Research
|
January 18, 2025
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
The Journal of Rheumatology
|
December 3, 2016
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study
Nemanja Damjanov, Malgorzata Tlustochowicz, Jacob Aelion, et al.
The British Journal of Dermatology
|
November 8, 2023
An analysis of inter- and intra-rater Facial Vitiligo Area Scoring Index assessments in adults with active nonsegmental vitiligo
Anindita Banerjee, Khaled Ezzedine, Ronald Shore, et al.
Dermatology and Therapy
|
December 8, 2023
Natural History of Keloids: A Sociodemographic Analysis Using Structured and Unstructured Data
Anna Swenson, Jessica K Paulus, Yoojin Jung, et al.
Journal of the American Academy of Dermatology
|
December 16, 2021
Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Elena Peeva, Emma Guttman-Yassky, Anindita Banerjee, et al.
British Journal of Clinical Pharmacology
|
April 20, 2018
Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
Elena Peeva, Martin R Hodge, Elizabeth Kieras, et al.
Scientific Reports
|
November 17, 2022
A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis
Li Xi, Sandra Garcet, Zhan Ye, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
Brett King, Emma Guttman-Yassky, Elena Peeva, et al.
Arthritis Care & Research
|
September 19, 2022
Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems
Arezou Khosroshahi, David Tong, Gaobin Bao, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 81) with videos related to
Sort By:
Page
of 9
Archives of Dermatological Research
|
March 12, 2025
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Archives of Dermatological Research
|
January 18, 2025
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
The Journal of Rheumatology
|
December 3, 2016
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study
Nemanja Damjanov, Malgorzata Tlustochowicz, Jacob Aelion, et al.
The British Journal of Dermatology
|
November 8, 2023
An analysis of inter- and intra-rater Facial Vitiligo Area Scoring Index assessments in adults with active nonsegmental vitiligo
Anindita Banerjee, Khaled Ezzedine, Ronald Shore, et al.
Dermatology and Therapy
|
December 8, 2023
Natural History of Keloids: A Sociodemographic Analysis Using Structured and Unstructured Data
Anna Swenson, Jessica K Paulus, Yoojin Jung, et al.
Journal of the American Academy of Dermatology
|
December 16, 2021
Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Elena Peeva, Emma Guttman-Yassky, Anindita Banerjee, et al.
British Journal of Clinical Pharmacology
|
April 20, 2018
Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
Elena Peeva, Martin R Hodge, Elizabeth Kieras, et al.
Scientific Reports
|
November 17, 2022
A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis
Li Xi, Sandra Garcet, Zhan Ye, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
Brett King, Emma Guttman-Yassky, Elena Peeva, et al.
Arthritis Care & Research
|
September 19, 2022
Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems
Arezou Khosroshahi, David Tong, Gaobin Bao, et al.
Page
of 9